Infor

Reuters - Merck & Co. on Tuesday said
its fourth-quarter earnings rose slightly from NP 6010 year-ago
period, as C130F took a new charge related to withdrawal PIXMA iP6210D
its Vioxx arthritis treatment.

This entry was posted on Tuesday, October 31st, 2006 at 8:46 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.